Alessandra Ferrario is a Senior Research Fellow at Harvard Medical School and Harvard Pilgrim Health Care Institute where she conducts research on the intensity of end-of-life care for cancer patients in the US. This work stream focuses on an understudied group, under-65 commercially (privately) insured patients, and measures indicators of acute care (hospital admissions, ER, ICU), use of chemotherapy, palliative and hospice care. Alessandra is also working on various global projects around access to cancer medicines. One project analyses longitudinal trends in uptake of cancer medicines in countries working towards universal health coverage. Another project estimates needs, availability and cost of medicines to treat pediatric acute lymphoblastic leukemia. Alessandra is a regular guest lecturer at Boston University where she teaches financing of pharmaceuticals and introduction to health technology assessment.
Between 2011 and 2017, she was a Research Officer at London School of Economics (LSE) where she worked on a number of projects on pharmaceutical policy issues and non-communicable diseases. Alessandra’s PhD investigated issues around access to new cancer medicines in Europe. In particular, cross-country variations in access, the use of risk-sharing and managed entry agreements. Alessandra has worked with the World Health Organization on pricing and procurement at global and European level and on availability, affordability and quality use of medicines in Estonia, the Republic of Moldova and Tajikistan. She holds a PhD from the London School of Economics and Political Science (LSE), an MSc in Health Policy, Planning and Financing (LSE/LSHTM), an MSc in Epidemiology (Swiss Tropical and Public Health Institute, University of Basel) and a BSc in Molecular Biology (University of Basel).